Arno Therapeutics Inactive 10-K2015 FY Annual report

Filed: 30 Mar 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adjunct, Allergy, Army, bacterium, Bellegrun, biodefense, Category, Classification, CRADA, delegate, Dozoretz, Eagle, enlargement, Equinox, Exploratory, FHC, Francisella, fungal, Germain, Gregory, Imputation, infection, Jay, Jean, John, Kiernan, Le, Luxembourg, Magainin, mandatorily, Michigan, microbial, Monnet, Moorin, mutation, NIAID, noncurrent, Nonqualified, Norfolk, Pathogen, people, promissory, ProQuest, prospectively, reacquired, Revocable, Rubin, spread, Squibb, Subtopic, titled, tularaemia, USAMRIID, VA, validly, Vestibular, virtually

Removed: accruing, amend, charge, Christopher, compounding, consented, debenture, disclaim, divided, exceeded, feature, Glenn, installment, Merck, occasion, owed, par, permitting, Randy, Registrable, resold, separately, sought, Thurman

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Arno Therapeutics similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements of Arno Therapeutics, Inc. on Forms S-8 (File No. 333-176664 and 333-194927) of our report dated March 30, 2016, which includes an emphasis of matter paragraph regarding the Company’s ability to continue as a going concern, relating to the financial statements appearing in this Annual Report on Form 10-K of Arno Therapeutics, Inc. for the year ended December 31, 2015.

/s/ Crowe Horwath LLP

New York, New York

March 30, 2016

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.